Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV.

Citation data:

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, ISSN: 1537-6591, Vol: 62, Issue: 12, Page: 1497-1504

Publication Year:
2016
Usage 12
Abstract Views 12
Captures 16
Readers 16
Citations 10
Citation Indexes 8
Clinical Citations 2
Repository URL:
https://touroscholar.touro.edu/tcopny_pubs/106; https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/ciw119
PMID:
26936665
DOI:
10.1093/cid/ciw119
PMCID:
PMC4885645
Author(s):
Del Bello, David; Cha, Agnes; Sorbera, Maria A.; Bichoupan, Kian; Levine, Calley; Doyle, Erin; Harty, Alyson; Patel, Neal; Ng, Michel; Gardenier, Donald; Odin, Joseph; Schiano, Thomas D.; Fierer, Daniel S.; Berkowitz, Leonard; Perumalswami, Ponni V.; Dieterich, Douglas T.; Branch, Andrea D. Show More Hide
Publisher(s):
Oxford University Press (OUP); Touro Scholar
Tags:
Medicine; HIV; hepatitis C; simeprevir; sofosbuvir; Pharmacy and Pharmaceutical Sciences; Virus Diseases
article description
Patients with hepatitis C virus (HCV) with or without human immunodeficiency virus (HIV) achieve high sustained virological response (SVR) rates on sofosbuvir (SOF)-containing regimens in clinical trials. Real world data on patients coinfected with HCV and HIV treated with SOF-based regimens are lacking.